TD Cowen Reaffirms Their Buy Rating on United Therapeutics (UTHR)

In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on United Therapeutics, with a price target of $675.00.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Thome covers the Healthcare sector, focusing on stocks such as United Therapeutics, Viridian Therapeutics, and Xenon. According to TipRanks, Thome has an average return of 21.7% and a 55.38% success rate on recommended stocks.

In addition to TD Cowen, United Therapeutics also received a Buy from Wells Fargo’s Benjamin Burnett in a report issued on May 7. However, on May 11, Oppenheimer assigned a Hold rating to United Therapeutics (NASDAQ: UTHR).

Based on United Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $781.5 million and a net profit of $274.9 million. In comparison, last year the company earned a revenue of $794.4 million and had a net profit of $322.2 million

Based on the recent corporate insider activity of 389 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year. Earlier this month, Nilda Mesa, a Director at UTHR sold 258.00 shares for a total of $150,137.94.